Medications for Reflux Esophagitis and Superficial Gastritis

Reflux esophagitis and superficial gastritis are both classified as acid-related disorders. The first-line treatment for these conditions typically involves the use of proton pump inhibitors (PPIs), which work by reducing stomach acid production. Commonly prescribed PPIs include lansoprazole, rabeprazole, omeprazole, pantoprazole, and ilaprazole. For reflux esophagitis, a standard treatment course usually lasts between 4 to 8 weeks. However, the duration of therapy for superficial gastritis may vary depending on the individual case and underlying causes.

In cases where gastritis is caused by Helicobacter pylori (H. pylori) infection, it's essential to undergo eradication therapy to eliminate the bacteria. This treatment generally lasts for 14 days and follows a "quadruple therapy" approach. The regimen includes one proton pump inhibitor, two different antibiotics, and one bismuth-containing compound. The PPI component can be selected from lansoprazole, rabeprazole, omeprazole, pantoprazole, or ilaprazole. Antibiotics often used in combination include amoxicillin, doxycycline, and furazolidone, with two chosen for the treatment. As for the bismuth agent, options such as colloidal bismuth pectin or bismuth potassium citrate are typically prescribed.

It's important to note that during the course of this therapy, patients may notice their stools or tongue turning black. This change is commonly associated with the use of bismuth-based medications and is generally harmless. Healthcare providers should inform patients about this potential side effect beforehand to prevent unnecessary concern or anxiety. Open communication helps ensure patient compliance and a smoother treatment process.